Heart-on-a-Chip (also called cardiac organ-on-a-chip or cardiac microphysiological system) is a microfluidic platform that recreates key structural and functional features of human heart tissue in a miniature, controllable format.
Core Components
- Cells: Usually human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs), often combined with cardiac fibroblasts and endothelial cells.
- 3D microenvironment: Cells are embedded in hydrogels (fibrin, collagen, Matrigel) inside microfluidic chambers.
- Mechanical support: Flexible pillars or membranes allow the tissue to contract and enable force measurement.
- Sensors: Optical, electrical, or mechanical sensors continuously record contractility, calcium handling, electrophysiology, and sometimes metabolic activity.
- Stimulation: Electrical pacing and mechanical stretch mimic physiological workload and promote maturation of the cardiomyocytes.
Key Capabilities
- Simultaneous measurement of multiple functional parameters (beating rate, force, action potentials, calcium transients).
- Application of controlled mechanical and electrical cues.
- Perfusion of media, drugs, or nanoparticles through integrated microchannels.
- Patient-specific modeling using iPSCs from individuals with genetic heart diseases.
- Recreation of disease states such as ischemia, arrhythmia, or cardiotoxicity.
Main Applications
- Early detection of drug-induced cardiotoxicity
- Disease modeling (genetic cardiomyopathies, myocardial infarction, heart failure)
- Screening of new cardiac drugs and nanomedicines
- Reduction of animal testing in preclinical research
- Personalized medicine approaches
Current State (2025–2026)
Advanced systems now include:
- Fully 3D-printed chips with integrated sensors
- Vascularized and perfusable models that allow blood-flow-like conditions
- Multi-organ platforms linking heart tissue with liver, kidney, or vasculature
- Improved maturation protocols combining 3D culture, metabolic cues (fatty acids, thyroid hormone), and electromechanical stimulation
Advantages over Traditional Models
- Higher physiological relevance than 2D cell cultures
- Human-specific responses (unlike animal models)
- Real-time, multi-parameter readout
- Lower cell and reagent consumption
- Potential for high-throughput screening
Remaining Challenges
- Full adult-like maturation of iPSC-cardiomyocytes is still incomplete
- Standardization and reproducibility across laboratories
- Cost and technical complexity
- Regulatory acceptance (some platforms are progressing through FDA’s ISTAND program)
Heart-on-a-Chip technology has evolved from simple contracting microtissues into sophisticated, sensor-equipped, and sometimes vascularized systems. It is currently one of the most promising tools for improving the predictive power of preclinical cardiac research.
